Antibiotic prophylaxis
|
210 (95.4%)
|
73 (93.6%)
|
133 (93.7%)
|
–
|
0.999
|
Ceftazidime
|
13 (5.9%)
|
7 (9.0%)
|
6 (4.2%)
|
2.055
|
0.229
|
Ceftriaxone
|
34 (15.4%)
|
14 (18.0%)
|
20 (14.1%)
|
0.589
|
0.440
|
Cefuroxime
|
109 (49.6%)
|
38 (48.7%)
|
71 (50.0%)
|
0.596
|
0.460
|
Meropenem
|
9 (4.1%)
|
3 (3.8%)
|
6 (4.2%)
|
0.018
|
0.999
|
Erythromycin
|
13 (5.9%)
|
5 (6.4%)
|
8 (5.6%)
|
0.055
|
0.774
|
Cefoperazone/Sulbactam
|
11 (5.0%)
|
2 (2.6%)
|
9 (6.3%)
|
1.512
|
0.334
|
Others
|
17 (7.7%)
|
4 (5.1%)
|
13 (9.2%)
|
1.148
|
0.428
|
Received empirical antibiotics
|
208 (94.6%)
|
73 (93.6%)
|
135 (95.1%)
|
0.241
|
0.758
|
Single antibiotics
|
75 (34.1%)
|
23 (29.5%)
|
52 (36.6%)
|
1.010
|
0.365
|
Ceftriaxone
|
11 (5.0%)
|
4 (5.13%)
|
7 (4.9%)
|
0.197
|
0.728
|
Meropenem
|
46 (20.9%)
|
15 (19.2%)
|
31 (21.8%)
|
0.211
|
0.798
|
Cefuroxime
|
4 (1.8%)
|
1 (1.3%)
|
3 (2.1%)
|
0.064
|
0.999
|
Vancomycin
|
14 (6.4%)
|
3 (3.8%)
|
11 (7.8%)
|
0.691
|
0.529
|
Combination antibiotics (2)
|
113 (51.4%)
|
42 (53.8%)
|
71 (50.0%)
|
0.466
|
0.560
|
Vancomycin + Meropenem
|
96 (43.6%)
|
35 (44.9%)
|
61 (43.0%)
|
0.138
|
0.788
|
Vancomycin + Ceftazidime
|
7 (3.2%)
|
3 (3.8%)
|
4 (2.8%)
|
0.103
|
0.710
|
Others
|
10 (4.6%)
|
4 (5.1%)
|
6 (4.2%)
|
0.038
|
0.999
|
Combination antibiotics (3)
|
28 (12.7%)
|
9 (11.5%)
|
19 (13.4%)
|
0.124
|
0.833
|
Vancomycin + Meropenem +Cefuroxime
|
8 (3.6%)
|
3 (3.8%)
|
5 (3.5%)
|
0.147
|
0.999
|
Vancomycin + Meropenem +Tinidazole
|
6 (2.7%)
|
3 (3.8%)
|
3 (2.1%)
|
1.116
|
0.352
|
Others
|
14 (6.4%)
|
3 (3.8%)
|
11 (7.8%)
|
1.474
|
0.420
|
Received definitive therapy
|
215 (97.7%)
|
74 (94.9%)
|
141 (99.3%)
|
4.436
|
0.055
|
Single antibiotics
|
67 (30.4%)
|
19 (24.4%)
|
48 (33.8%)
|
1.584
|
0.220
|
Meropenem
|
61 (27.7%)
|
16 (20.5%)
|
45 (31.7%)
|
1.519
|
0.341
|
Ceftriaxone
|
4 (1.8%)
|
2 (2.6%)
|
2 (1.4%)
|
0.981
|
0.371
|
Colistin
|
2 (0.9%)
|
1 (1.3%)
|
1 (0.7%)
|
0.475
|
0.490
|
Combination antibiotics (2)
|
128 (58.2%)
|
48 (61.5%)
|
80 (56.3%)
|
1.331
|
0.306
|
Vancomycin + Meropenem
|
105 (47.7%)
|
39 (50.0%)
|
66 (46.5%)
|
0.032
|
0.999
|
Vancomycin + Ceftazidime
|
8 (3.6%)
|
3 (3.8%)
|
5 (3.5%)
|
0.001
|
0.999
|
Meropenem + Tigecycline
|
8 (3.6%)
|
2 (2.6%)
|
6 (4.2%)
|
0.569
|
0.709
|
Others
|
7 (3.2%)
|
4 (5.1%)
|
3 (2.1%)
|
1.219
|
0.424
|
Combination antibiotics (3)
|
20 (9.1%)
|
7 (9.0%)
|
13 (9.2%)
|
0.003
|
0.999
|
Colistin+ Meropenem + Trimethoprim
|
7 (3.2%)
|
2 (2.6%)
|
5 (3.5%)
|
0.196
|
0.999
|
Colistin+ Tigecycline + Meropenem
|
6 (2.7%)
|
3 (3.8%)
|
3 (2.1%)
|
0.848
|
0.613
|
Others
|
7 (3.2%)
|
2 (2.6%)
|
5 (3.5%)
|
0.196
|
0.999
|
Clinical Outcome
|
Improved and cured
|
184 (83.6%)
|
62 (79.5%)
|
122 (85.9%)
|
1.520
|
0.254
|
Mortality attributed to infection
|
26 (11.8%)
|
14 (18.0%)
|
12 (8.4%)
|
4.358
|
0.049
|
Mortality not attributed to infection
|
10 (4.6%)
|
2 (2.6%)
|
8 (5.6%)
|
1.093
|
0.500
|